Form 4: BridgeBio Officer's Stock Withholding for Taxes

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the disposition of 4,781 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), reported a transaction on August 16, 2025.
• The transaction involved the disposition of 4,781 shares of BBIO common stock.
• These shares were withheld by the issuer at a price of $51.32 per share to satisfy tax obligations.
• This withholding was in connection with the vesting of 9,409 Restricted Stock Units (RSUs) held by Ms. Apuli.
• Following this transaction, Ms. Apuli directly beneficially owns 137,078 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding related to RSU vesting, which is a non-discretionary event and does not indicate any particular positive or negative sentiment about the company's future performance.

Positives

• Indicates the vesting of Restricted Stock Units (RSUs), which is a positive event for the employee as it represents compensation becoming fully owned.
• The transaction was a routine tax withholding, not a discretionary sale, suggesting no negative sentiment from the officer regarding the company's prospects.

Negatives

• A reduction in the officer's direct shareholding, albeit for tax purposes.

Future Outlook

No forward-looking statements or guidance provided.

Industry Context

This is a routine insider transaction related to executive compensation. It does not provide broader industry trends or competitive insights. It reflects standard practice for RSU vesting where a portion of shares is withheld to cover income taxes.

Comparison to Industry Standards

• This is a standard practice for executive compensation and tax management related to RSU vesting across various industries. No specific comparable companies or projects are relevant for this type of individual transaction.

Related Party Transactions

• This is a transaction between an officer (Maricel Apuli) and the issuer (BridgeBio Pharma, Inc.) related to executive compensation, which is a common type of related party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact. This is a routine, non-discretionary transaction. It slightly increases the float of shares available for trading but is not indicative of a change in company fundamentals or strategy.
• Employees: Reflects standard executive compensation practices, which can be a positive for employee morale and retention.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary transaction where shares were withheld to cover tax obligations upon RSU vesting. It does not provide new information about the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. It is a standard compensation-related event for an executive.

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, insider transaction, stock withholding, RSU vesting, executive compensation, Maricel Apuli, Chief Accounting Officer